[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Takeda Pharmaceutical Ltd ADR (TAK)

Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 53,975,756
  • Shares Outstanding, K 3,182,533
  • Annual Sales, $ 29,738 M
  • Annual Income, $ -1,006 M
  • EBIT $ 2,182 M
  • EBITDA $ 8,982 M
  • 60-Month Beta -0.07
  • Price/Sales 1.90
  • Price/Cash Flow 5.44
  • Price/Book 1.10

Options Overview Details

View History
  • Implied Volatility 37.77% (+10.48%)
  • Historical Volatility 27.44%
  • IV Percentile 88%
  • IV Rank 36.58%
  • IV High 72.40% on 10/29/25
  • IV Low 17.80% on 08/15/25
  • Expected Move (DTE 8) 0.13 (0.76%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 118
  • Volume Avg (30-Day) 51
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 5,686
  • Open Int (30-Day) 7,901
  • Expected Range 16.62 to 16.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.39
  • Number of Estimates 1
  • High Estimate $0.39
  • Low Estimate $0.39
  • Prior Year $0.52
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.34 +9.23%
on 06/17/26
17.12 -2.16%
on 07/07/26
+1.01 (+6.42%)
since 06/08/26
3-Month
14.84 +12.87%
on 06/03/26
18.60 -9.95%
on 04/09/26
-1.91 (-10.24%)
since 04/08/26
52-Week
12.99 +28.95%
on 10/30/25
18.90 -11.35%
on 04/01/26
+1.73 (+11.52%)
since 07/08/25

Most Recent Stories

More News
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO

Board of Directors appoints Julie Kim as Representative Director, President & CEO following shareholder vote Announces new appointments and assignments of directors ...

TAK : 16.75 (-1.24%)
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1

- Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms...

TAK : 16.75 (-1.24%)
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated...

TAK : 16.75 (-1.24%)
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease

If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's disease ...

TAK : 16.75 (-1.24%)
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda

Plaintiffs’ attorneys celebrate massive antitrust win against rising pharmaceutical costs

TAK : 16.75 (-1.24%)
Takeda Pharmaceutical Q4 Earnings Call Highlights

Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around three...

TAK : 16.75 (-1.24%)
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches Achieved Latest FY2025 Management Guidance ...

TAK : 16.75 (-1.24%)
Can Takeda's Pipeline Progress Finally Translate Into Guidance the Street Wants to Hear?

Barchart Research What to Expect from TAK Earnings TAK Generated May 12, 2026 Current Price $16.42 EPS Estimate $$0.21 Consensus Rating Moderate Buy Average Move 3.15% Can Takeda's Pipeline Progress Finally...

TAK : 16.75 (-1.24%)
Home Sales, Inflation to be Released This Week

Monday U.S. Economic Lookahead Existing home sales (April) Featured Earnings ...

SONY : 21.15 (-1.17%)
AMAT : 570.50 (+2.89%)
VIV : 13.29 (+0.08%)
CSCO : 113.82 (+1.82%)
CEG : 244.52 (+2.01%)
NU : 13.37 (-1.76%)
FLO : 8.37 (-2.67%)
SPG : 219.09 (-3.57%)
BN : 42.93 (-1.96%)
SE : 105.31 (+1.04%)
RBC : 593.89 (-1.06%)
USAS : 4.21 (-3.88%)
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients

TAK : 16.75 (-1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

3rd Resistance Point 16.89
2nd Resistance Point 16.85
1st Resistance Point 16.80
Last Price 16.75
1st Support Level 16.71
2nd Support Level 16.67
3rd Support Level 16.62

See More

52-Week High 18.90
Last Price 16.75
Fibonacci 61.8% 16.64
Fibonacci 50% 15.94
Fibonacci 38.2% 15.25
52-Week Low 12.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.